Overcome bottlenecks in viral vector manufacturing

October 21, 2021

The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developing a clinic-bound therapeutic. Join Dr. Igor Oruetexebarria, senior scientist at Kuopio Center for Gene and Cell Therapy, as he walks through some of the current challenges in the field of gene therapy AAV development, and explains how the nanoDSF and DLS capabilities of the Prometheus Panta have improved the outcomes for his vector candidates.

Previous Article
Journey of an mAb through IND and BLA filing
Journey of an mAb through IND and BLA filing

Up next
Prometheus Panta adds DLS to the new gold standard for challenging stability characterization
Prometheus Panta adds DLS to the new gold standard for challenging stability characterization

Learn what attributes Prometheus users considered a must-have and how we made sure to preserve them when in...

Ready to tackle your challenging stability characterizations?

Discover tools